← Back to Search

Behavioral Intervention

Therapy and Peer Support for Opioid Use Disorder

N/A
Recruiting
Led By David S Festinger, Ph.D.
Research Sponsored by Public Health Management Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at baseline and 3,6,9, 12-month assessments
Awards & highlights
No Placebo-Only Group

Summary

This trial aims to find the best ways to help people with opioid use disorder by combining medication with different types of therapy. The researchers are working with former patients to understand what treatments work best for different individuals

Who is the study for?
This trial is for individuals with Opioid Use Disorder who are currently on medication-assisted treatment. It's designed to explore the benefits of adding psychosocial support to their regimen. Participants should be interested in how different psychological treatments can complement their current therapy.
What is being tested?
The study is testing various forms of psychosocial treatment as a component of medication-assisted therapy for opioid addiction. The aim is to find out which approaches work best for different patients, moving away from generic treatments and towards more personalized care.
What are the potential side effects?
Since the interventions being studied are psychosocial in nature, they may include emotional distress or discomfort during sessions, potential changes in mood or behavior, but no physical side effects like those associated with medications.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at baseline and 3,6,9, 12-month assessments
This trial's timeline: 3 weeks for screening, Varies for treatment, and at baseline and 3,6,9, 12-month assessments for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Changes in urinalysis-confirmed opioid use from baseline through one year post-study entry
Secondary study objectives
Changes in ED utilization from baseline to one year post-study entry
Changes in multidimensional problem severity from baseline through one year post-study entry
Changes in opioid overdose rates
+4 more
Other study objectives
Job satisfaction and stress

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

4Treatment groups
Active Control
Group I: MAT- OBOTActive Control1 Intervention
Those randomized to MAT standard of care will continue to receive standard office-based buprenorphine treatment.
Group II: MAT+ both CBT and CRS/Peer Support SpecialistActive Control1 Intervention
Those randomized to MAT+ office-based CBT will receive office-based buprenorphine treatment along with office-based CBT and a CRS.
Group III: MAT+ CRS/Peer Support SpecialistActive Control1 Intervention
Those randomized to MAT+ office-based CBT will receive office-based buprenorphine treatment along with a CRS.
Group IV: MAT+ office-based CBTActive Control1 Intervention
Those randomized to MAT+ office-based CBT will receive office-based buprenorphine treatment along with office-based CBT.

Find a Location

Who is running the clinical trial?

Philadelphia College of Osteopathic MedicineOTHER
10 Previous Clinical Trials
877 Total Patients Enrolled
Patient-Centered Outcomes Research InstituteOTHER
573 Previous Clinical Trials
27,077,862 Total Patients Enrolled
Boston UniversityOTHER
470 Previous Clinical Trials
9,987,416 Total Patients Enrolled
~79 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top